Home / Intelligence / Podcasts / Measures the Life Sciences Industry Can Take to Facilitate Diversity in Clinical Trials
The importance of ensuring diversity in clinical trials is undisputed, but barriers across the healthcare ecosystem still exist; what can healthcare regulators, policy makers, and manufacturers do to overcome challenges when recruiting clinical trial participants?
Host, Matthew Rube, a Senior Consultant at Trinity Life Sciences, joins two of the subject-matter experts that authored Trinity Life Sciences’ cornerstone white paper to discuss why ensuring diversity in clinical trials participation is such a critical issue, the results of the team’s research, and the action-oriented recommendations that they have for the life sciences industry.
Featuring:
Michele Andrews
Principal, Strategic Advisory &
Head of Dynamic Market Intelligence
Monique Marsh
Associate Director of Primary Market Research & Head of Qualitative Innovation and Implementation
HOST: Matthew Rube
Senior Consultant,
Evidence, Value, Access and Pricing
Download the White Paper: Diversity in Clinical Trials Participation: A Life Sciences Perspective to understand how you and your organization can help to further diversity in clinical trials.
Thank you to everyone who contributed towards this important research:
Peter Palumbo, Patrick Hong, Monique Marsh, Shanice O’Brien, Courtney Poopat, Catherine Toal, Michele Andrews, Herman Sanchez, Sumudu Dehipawala, UT Yadav, Alexander Fish, Peter Baek, Alessandra Moscoso, Shruti Nambiar, and Justin Li
Related Intelligence
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
Available On Demand
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Watch Now
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA). Ahead of ISPOR EU, Trinity’s HTA […]
Read More
Webinars
Diversity in Clinical Trials: Evaluating Current Initiatives and the Impending Impact of the FDA’s Guidance
Available On Demand
Trinity’s Diversity, Equity & Inclusion (DEI) strategy team invites life sciences executives to join a lively discussion on recent research and developments in clinical trial diversity with a focus on racial and ethnic minorities. Herman Sanchez, Chief Business Officer at Trinity Life Sciences, will host this session and moderate a panel with special guests Monique […]
Watch Now